Article
Oncology
Nathalie M. Grob, Roger Schibli, Martin Behe, Thomas L. Mindt
Summary: Several radiolabeled peptides targeting CCK2R-positive cancers have been investigated, with some showing promising tumor-targeting properties. By applying chemical modifications to the peptide Lu-177-PP-F11N, improved radiolabeled peptidomimetics were developed with enhanced tumor uptake and retention, making them promising candidates for imaging and therapy of CCK2R-positive tumors. The use of stable 1,2,3-triazoles as amide bond bioisosteres proved to be a successful strategy in improving the tumor-targeting properties of the peptides.
Review
Pharmacology & Pharmacy
Tyrillshall S. T. Damiana, Simone U. Dalm
Summary: Radionuclide therapy and targeted radionuclide therapy have gained interest in cancer treatment, but only a small percentage of patients achieve complete response. Therefore, combining these treatments with other anti-cancer therapies may be a promising strategy to improve outcomes.
Article
Oncology
Kim R. Kennedy, John Harvey Turner, William B. G. MacDonald, Phillip G. Claringbold, Glenn Boardman, David T. Ransom
Summary: This study retrospectively analyzed the long-term toxicity and survival outcomes of 104 patients with advanced NETs treated with Lu-177-octreotate PRRT. The results showed that Lu-177-octreotate PRRT can provide durable responses and is well tolerated in long-term follow-up. However, the 6.7% long-term risk of MDS/leukemia needs to be balanced against the 21% PFS at 10 years.
Review
Oncology
Elettra Merola, Chiara Maria Grana
Summary: This article discusses the use of peptide receptor radionuclide therapy (PRRT) as an essential treatment method for advanced, unresectable neuroendocrine tumors. It covers the multidisciplinary theranostic approach, treatment effectiveness, patient outcomes, and toxicity of PRRT for neuroendocrine neoplasms. Important research and new radiopharmaceuticals for the treatment of these patients are explored.
Article
Radiology, Nuclear Medicine & Medical Imaging
Noemie S. Minczeles, Casper H. J. van Eijck, Marjon J. van Gils, Marie-Louise F. van Velthuysen, Els J. M. Nieveen van Dijkum, Richard A. Feelders, Wouter W. de Herder, Tessa Brabander, Johannes Hofland
Summary: Early administration of PRRT followed by surgery is associated with favorable long-term outcomes in patients with locally advanced or oligometastatic panNEN.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Oncology
Amichay Meirovitz, Karny Shouchane Blum, Alexander Maly, Evgeniya Bersudski, Nir Hirshoren, Ross Abrams, Aron Popovtzer, Marina Orevi, Jeffrey Weinberger
Summary: This study confirms the expression of SSTR2 in glandular salivary carcinomas and an inverse correlation in expression levels between SSTR2 and Ki-67. This lays a foundation for novel treatment options in salivary metastatic cancers where SSTR2 may be a potential novel therapeutic target.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Endocrinology & Metabolism
Sriram Gubbi, Mohammad Al-Jundi, Jaydira Del Rivero, Abhishek Jha, Marianne Knue, Joy Zou, Baris Turkbey, Jorge Amilcar Carrasquillo, Emily Lin, Karel Pacak, Joanna Klubo-Gwiezdzinska, Frank I-Kai Lin
Summary: The study reported a case of a patient who developed symptomatic primary hypothyroidism after receiving Lu-177-DOTATATE therapy, with notable changes in TFTs and thyroid auto-antibody titers before and after treatment. Functional imaging revealed diffuse uptake of Lu-177-DOTATATE in the thyroid gland.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Chemistry, Multidisciplinary
Prachi Desai, Rahul Rimal, Sabri E. M. Sahnoun, Felix M. Mottaghy, Martin Moller, Agnieszka Morgenroth, Smriti Singh
Summary: Endogenous targeted radiotherapy has side effects, and the use of nanocarriers can mitigate these effects. Nanocarriers have advantages of prolonging circulation time, increasing tumor retention, and offering multifunctionality for targeting strategies.
Article
Oncology
Sang Hee Lee, Ji Young Choi, Jae Ho Jung, In Ho Song, Hyun Soo Park, Nunzio Denora, Francesco Leonetti, Sang Eun Kim, Byung Chul Lee
Summary: The study demonstrated that integrin-targeted PRRT combined with TMZ significantly reduced tumor volume in glioblastoma, showing a superior effect compared to using each agent individually. The combination therapy proved to be an effective new medical tool for treating glioblastoma.
Article
Radiology, Nuclear Medicine & Medical Imaging
Aleksandra Sygula, Aleksandra Ledwon, Kornelia Hasse-Lazar, Beata Jurecka-Lubieniecka, Barbara Michalik, Ewa Paliczka-Cieslik, Marcin Zeman, Ewa Chmielik, Monika Sczasny, Barbara Jarzab, Daria Handkiewicz-Junak
Summary: This study aimed to evaluate the benefits of using SSAs following PRRT in patients with NEN. The results showed that subsequent SSA treatment did not lead to improved PFS or OS in patients with disease control after PRRT, indicating the need for further evaluation in future studies.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Review
Medicine, General & Internal
Christina-Katharina Fodi, Jens Schittenhelm, Juergen Honegger, Salvador Guillermo Castaneda-Vega, Felix Behling
Summary: Meningiomas, the most common primary intracranial tumors, can be cured by surgery or stabilized by radiation. However, recurrent and aggressive tumors have no established alternative treatments. Studies have shown that meningiomas express somatostatin receptors, which can be targeted with peptide radioreceptor therapy used for neuroendocrine tumors. Optimization of this treatment option can be achieved through the development of new substances and specific adaptations for different meningioma subtypes.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Noemie S. Minczeles, Wouter W. de Herder, Richard A. Feelders, Frederik A. Verburg, Johannes Hofland, Tessa Brabander
Summary: The aim of this study was to analyze the efficacy of submaximal activities of PRRT in patients who discontinued treatment for non-disease-related reasons. The results showed that patients receiving a reduced activity had lower tumor response and survival compared to patients who received the intended cumulative activity of 29.6 GBq Lu-177-DOTATATE.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Xiaojing Lu, Cuncun Lu, Yongjie Yang, Xiangfen Shi, Haibo Wang, Nan Yang, Kehu Yang, Xiaojian Zhang
Summary: By conducting bibliometric analysis on PRRT research literature from 2000 to 2019, this study revealed a rapid growth in publication outputs, with Germany being the largest contributor. Key topics included efficacy, adverse effects, standardization, and individual dose optimization of PRRT.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Clinical Neurology
Dominik Lisowski, Philipp E. Hartrampf, Natalie Hasenauer, Vera Nickl, Camelia-Maria Monoranu, Joerg Tamihardja
Summary: This case report describes a rare malignant meningioma case in which the patient developed multiple metastases in bones, lungs, and liver after complete resection of the primary tumor. The loss of E-cadherin adhesion molecules was associated with tumor invasion and distant metastasis formation. Systemic therapy, including PRRT, has limited efficacy for malignant meningioma patients.
Review
Oncology
N. S. Minczeles, J. Hofland, W. W. de Herder, T. Brabander
Summary: PRRT with [Lu-177-DOTA(0),Tyr(3)] octreotate is effective and safe for patients with low-grade advanced gastroenteropancreatic neuroendocrine neoplasms, with potential extensions and new approaches to further improve treatment efficacy and safety. Recent research has shown promising results in other NENs, with various strategic approaches having the potential to enhance the outcome of PRRT. Multiple preclinical and early clinical studies have shown encouraging potential to advance the clinical outcome of PRRT in NEN patients.
CURRENT ONCOLOGY REPORTS
(2021)